Autolus Therapeutics plc (AUTL) Options Positioning, Max Pain & Unusual Sweeps

Per the Roarable RQD rating, AUTL scores 21 out of 100, earning a letter grade of E and the verdict label "Roarable Strong Sell — Forensic Risk / Avoid." The fundamental cash engine pillar scores 3 / 20 (ROIC -35%; FCF yield 0%), indicating that the business is not currently generating returns on capital or free cash flow. The whale 13F flow pillar scores 4 / 20 (institutional accumulation and options positioning), suggesting weak institutional support in the rating's inputs. The insider conviction pillar scores 3 / 20 (SEC Form 4 and Congressional PTR cluster flow), indicating little supportive insider signaling. The macro regime fit pillar scores 6 / 20 (Beta 1.0; sector sensitivity), a middling reading on market sensitivity. The forensic balance sheet pillar scores 5 / 20 (Altman Z 0.2; Piotroski F 3/9; Debt/Equity 0.5), the most direct signal of financial stress in the rating. For a prospective investor, the upside case depends on a turnaround in cash generation that the reported figures do not yet show, while the valuation tradeoff is that earnings-based multiples cannot be assessed from available data. Second-order risk is elevated because weak balance-sheet and cash-flow pillars can amplify sensitivity to any financing or operating setback. This is an analytical summary, not personalized financial advice.

Per the SEC financials, revenue rose from $1.7M (FY 2023) to $10.1M (FY 2024) to $75.4M (FY 2025), while operating losses and net losses remained large in each period. Per the market data, gross margin is -27.8%, operating margin is -60%, net margin is -60%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 0.2 and the Piotroski F-Score is 3/9, with Debt/Equity of 0.5. Reported cash declined from $227.4M (FY 2024) to $104.1M (FY 2025), and FY 2025 free cash flow was $-302.6M.

Per the recent news and catalysts feed, six headlines are tagged to AUTL, all with a relative time within the past 15 hours. One item, a Yahoo Finance report, is labeled CATALYST and carries a GREEN light; it is titled "All You Need to Know About Autolus Therapeutics (AUTL) Rating Upgrade to Buy." The remaining five items are labeled MARKET WIRE with YELLOW lights, including a Seeking Alpha piece titled "Autolus Therapeutics: Key Questions For The Near Term" and a kalkine.ca piece titled "Why Is Autolus Therapeutics (NASDAQ:AUTL) Down 10.92% Pre-Market, and Is More Selling Ahead?" Risk watch items include the Seeking Alpha headline "Autolus Therapeutics: Cheap On Sales, Still Far From Breakeven." Per the Butterfly Supply-Chain Graph, the supply chain is NONE, with no butterfly links and no proprietary signals.

• What are Autolus's reported product lines and customer base, and what drives the revenue increase from $1.7M to $75.4M across FY 2023–FY 2025?
• What is the company's debt position, since the debt field is N/A for all reported periods?
• What is the basis for the "Rating Upgrade to Buy" headline, and which analyst or source issued it?
• What is the company's cash runway given cash of $104.1M against FY 2025 free cash flow of $-302.6M?
• What EPS and P/E figures would apply, since EPS and valuation multiples are not available in the source data?